Latest Articles

The UK’s national health system needs to take a hard look at their priorities and procedures to ensure that rapid advances in molecular diagnostics in lung cancer are translated into a practical service for all patients, according to a report launched at the British Thoracic Oncology Group Annual Conference.

Liquid biopsies for cancer search for evidence of disease biomarkers, the most common of which include circulating tumor cells, cell-free nucleic acids, exosomes, proteins and phosphoproteins. Read on for insights on advances in the field that could revolutionize clinical oncology practice.

Christie Hunter is the Director of Applications at SCIEX where her and her team are tasked with developing new applications for SCIEX products, from screening for pesticides in our food supply through to molding the way cancer biomarkers are found. We spoke to Christie about her career, achievements and challenges for the future.

Looking at the industry growth and the complexities of biopharma development, it is no wonder that transformational developments are required to better equip laboratories and operations in biopharma.

Thanks to advances in therapeutics, chronic myeloid leukemia has been transformed from a deadly cancer into a manageable, chronic condition. However, patients have to stay on these drugs their whole lives, as there isn't a diagnostic test sensitive enough to detect traces of the disease that threaten a relapse. This article delves into the unmet need for such a test, and explains why droplet digital PCR (ddPCR) is a strong candidate that may fill this gap.

Artificial intelligence (AI) is developing rapidly and becoming integrated into our daily lives. How is AI advancing medical imaging in the diagnostics world?

We are entering uncharted territory in biopharmaceutical development. Emerging new classes of treatments are harnessing the natural power of viruses and cells and engineering them to fight human diseases. As our arsenal of conventional therapies begins to fail, a new army of biotherapeutics is on the horizon. Here, we look at two new classes of treatments leading the charge.

A single bacterial cell on its own is vulnerable to attack and like many living things they can benefit from safety in numbers. But bacteria take communal living to a whole new level, forming veritable civilizations - the bacterial biofilm.

In this article, we explore two novel high-throughput analytical methods based on liquid chromatography-mass spectrometry (LC-MS) analysis that can augment early drug screening and biomarker detection in the clinic.

To achieve regulatory compliance and authorization for sale in Europe, every medical device must be supported by a Clinical Evaluation Report which documents the entire clinical evaluation process. Read on for recommendations on how manufacturers can keep up with the changing regulation landscape.